Millipore Sigma Vibrant Logo

05-883 Anti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043

View Products on Sigmaaldrich.com
05-883
100 µg  
가격 검색...
가격을 검색할 수 없습니다
Minimum Quantity needs to be mulitiple of
Maximum Quantity is
가격 문의 추가 정보
()이 할인됨
 
가격 문의
현재 재고 없음
현재 재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      특별 제공

       

      고객 서비스로 문의

      개요

      Replacement Information

      주요 사양표

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HELISA, WBMPurifiedMonoclonal Antibody
      Description
      Catalogue Number05-883
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043
      References
      Product Information
      FormatPurified
      Presentation100 µg of protein G purified mouse IgG1 lyophilized from 10 mM NaH2PO4, 0.15 M NaCl, 1.0% mannitol, pH 7.4.
      Quality LevelMQ100
      Applications
      ApplicationDetect tPA (Tissue Plasminogen Activator) using this Anti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043 validated for use in ELISA & WB.
      Key Applications
      • ELISA
      • Western Blotting
      Biological Information
      ImmunogenPurified human tissue plasminogen activator (tPA)
      Cloneclone GMA-043
      HostMouse
      SpecificitytPA
      IsotypeIgG1
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes tissue-type plasminogen activator, a secreted serine protease which converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme. Tissue-type plasminogen activator is synthesized as a single chain which is cleaved by plasmin to a two chain disulfide linked protein. This enzyme plays a role in cell migration and tissue remodeling. Increased enzymatic activity causes hyperfibrinolysis, which manifests as excessive bleeding; decreased activity leads to hypofibrinolysis which can result in thrombosis or embolism. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms.
      Gene Symbol
      • PLAT
      • Reteplase
      • reteplase
      • T-PA
      • alteplase
      • DKFZp686I03148
      • Alteplase
      • tPA
      • TPA
      Purification MethodProtein G Purified
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P00750 # Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration.
      SIZE: 562 amino acids; 62917 Da
      SUBUNIT: Heterodimer of chain A and chain B held by a disulfide bond. Binds to fibrin with high affinity. This interaction leads to an increase in the catalytic efficiency of the enzyme between 100-fold and 1000-fold, due to an increase in affinity for plasminogen. Similarly, binding to heparin increases the activation of plasminogen. Binds to annexin A2, cytokeratin-8, fibronectin and laminin. Binds to mannose receptor and the low- density lipoprotein receptor-related protein (LRP1); these proteins are involved in TPA clearance. Yet unidentified interactions on endothelial cells and vascular smooth muscle cells (VSMC) lead to a 100-fold stimulation of plasminogen activation. In addition, binding to VSMC reduces TPA inhibition by PAI-1 by 30-fold. Binds LRP1B; binding is followed by internalization and degradation.
      SUBCELLULAR LOCATION: Secreted, extracellular space.
      TISSUE SPECIFICITY: Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
      DOMAIN: SwissProt: P00750 Both FN1 and one of the kringle domains are required for binding to fibrin. & Both FN1 and EGF-like domains are important for binding to LRP1. & The FN1 domain mediates binding to annexin A2. & The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site.
      PTM: The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa. & Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two- chain type II glycoform in the presence of fibrin. & N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor. & Characterization of O-linked glycan was studied in Bowes melanoma cell line.DISEASE:SwissProt: P00750 # Increased activity of TPA causes hyperfibrinolysis, with excessive bleeding as a consequence. & Defective release of TPA causes hypofibrinolysis, leading to thrombosis or embolism.
      SIMILARITY: Belongs to the peptidase S1 family. & Contains 1 EGF-like domain. & Contains 1 fibronectin type-I domain. & Contains 2 kringle domains. & Contains 1 peptidase S1 domain.
      Molecular WeightMr 63kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assuranceroutinely evaluated by immunoblot on human tPA
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage Conditionsstable 2 years at -20°C from date of shipment
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      카탈로그 번호 GTIN
      05-883 04053252670435

      Documentation

      Anti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043 MSDS

      타이틀

      물질안전보건자료(MSDS) 

      Anti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043 Certificates of Analysis

      TitleLot Number
      Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2387482 2387482
      Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2446690 2446690
      Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) 2981172
      Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) 3134099
      Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) 3117837
      Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 1956576 1956576
      Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2030004 2030004
      Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2219270 2219270
      Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2283788 2283788
      Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2302726 2302726

      References

      Reference overviewPub Med ID
      Tissue plasminogen activator as a modulator of neuronal survival and function
      Tsirka, Stella E
      Biochem Soc Trans, 30:222-5 (2002)  2002

      12023855 12023855
      Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice
      Gladstone, D J and Black, S E
      CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 165:311-7 (2001)  2001

      11517650 11517650
      Tissue-type plasminogen activator: characteristics, applications and production technology.
      Rouf, S A, et al.
      Biotechnol. Adv., 14: 239-66 (1996)  1996

      요약 표시
      14537155 14537155